Table 3.
Summary of AEs (safety analysis set).
Atezolizumab + bevacizumab | |
---|---|
N = 43 | |
Any AE | 41 (95.3) |
Grade ≥3 AE | 11 (25.6) |
AE leading to treatment interruption | 7 (16.3) |
AE leading to treatment discontinuation | 2 (4.7) |
AE leading to death | 1 (2.3) |
Atezolizumab-related AE | 39 (90.7) |
Atezolizumab-related serious AE | 7 (16.3) |
Bevacizumab-related AE | 38 (88.4) |
Bevacizumab-related serious AE | 7 (16.3) |
Note: Data are n (%).